[Therapy of MS symptoms. Here also are guidelines necessary].
T
T
Henze
K V
KV
Toyka
D002491:Central Nervous System Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003245:Consensus Statements as Topic; D019317:Evidence-Based Medicine; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000150:complications / Q000175:diagnosis / Q000534:rehabilitation*; D010166:Palliative Care / Q000379:methods*; D017410:Practice Guidelines as Topic
D002491:Central Nervous System Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents